AIC
NTLA icon

Ameritas Investment Company’s Intellia Therapeutics NTLA Stock Holding History

Ameritas Investment Company’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,600
Closed -$31K – 1158
2020
Q1 		$31K Buy
+2,600
New +$35K 0.01% 856
2019
Q2 		– Sell
-1,635
Closed -$28K – 640
2019
Q1 		$28K Buy
+1,635
New +$24.4K 0.01% 508

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameritas Investment Company's NTLA Position: Q2 2020 in Review

Ameritas Investment Company sold out of Intellia Therapeutics (NTLA) in Q2 2020, closing a stake of 2,600 shares — an estimated $31K sold.

Ameritas Investment Company first reported a position in NTLA in Q1 2019 and held it in 2 quarters. The position peaked at $31K in Q1 2020. 164 funds tracked by Wall St. Rank hold NTLA as of Q2 2020.

  • Ameritas Investment Company reported no remaining Intellia Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Ameritas Investment Company sold 2,600 Intellia Therapeutics shares in Q2 2020, an estimated $31K.
  • Ameritas Investment Company first reported a position in Intellia Therapeutics in Q1 2019 and held it in 2 quarters.
  • Ameritas Investment Company's Intellia Therapeutics position peaked at $31K in Q1 2020.
  • 164 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2020.

Based on Ameritas Investment Company's 13F filing for Q2 2020, filed 14 Aug 2020.